mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Velphoro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Velphoro.

For practical information about using Velphoro, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 30/06/2020

Authorisation details

Product details
Agency product number
Active substance
mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches
International non-proprietary name (INN) or common name
mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches
Therapeutic area (MeSH)
  • Hyperphosphatemia
  • Renal Dialysis
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Vifor Fresenius Medical Care Renal Pharma France
Date of issue of marketing authorisation valid throughout the European Union
Contact address
100-101 Terrasse Boieldieu
Tour Franklin- La Défense 8
92042 Paris la Défense Cedex

Product information

14/05/2020 Velphoro - EMEA/H/C/002705 - II/0021


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of hyperkalemia and hyperphosphatemia

Therapeutic indication

Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).

Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.

Assessment history

How useful was this page?

Add your rating